Contrasting Cue Biopharma (CUE) & The Competition

Cue Biopharma (NASDAQ:CUE) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Cue Biopharma to related businesses based on the strength of its institutional ownership, risk, earnings, analyst recommendations, valuation, profitability and dividends.

Volatility and Risk

Cue Biopharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, Cue Biopharma’s rivals have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cue Biopharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cue Biopharma	$27.47 million	-$26.60 million	-0.69
Cue Biopharma Competitors	$705.29 million	$10.71 million	-15.00

Cue Biopharma’s rivals have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cue Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1	1	0	1	2.33
Cue Biopharma Competitors	9829	15119	45431	1586	2.54

Cue Biopharma presently has a consensus price target of $83.00, suggesting a potential upside of 343.14%. As a group, “Biotechnology” companies have a potential upside of 102.32%. Given Cue Biopharma’s higher possible upside, research analysts clearly believe Cue Biopharma is more favorable than its rivals.

Institutional and Insider Ownership

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cue Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Cue Biopharma Competitors	-12,357.18%	-197.96%	-30.56%

Summary

Cue Biopharma rivals beat Cue Biopharma on 7 of the 12 factors compared.

Cue Biopharma Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.